PXMTF (PHAXIAM Therapeutics) Short-Term Debt: $0.00 Mil (As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics Short-Term Debt?

PHAXIAM Therapeutics PXMTF 38 Short-Term Debt is $0.00 Mil as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

PHAXIAM Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

PHAXIAM Therapeutics's quarterly Short-Term Debt declined from Dec. 2022 ($2.72 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

PHAXIAM Therapeutics's annual Short-Term Debt declined from Dec. 2020 ($2.76 Mil) to Dec. 2021 ($0.19 Mil) but then increased from Dec. 2021 ($0.19 Mil) to Dec. 2022 ($2.72 Mil).

PHAXIAM Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PHAXIAM Therapeutics Short-Term Debt Related Terms

PHAXIAM Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Short-Term Debt Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.00 2.76 0.19 2.72

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 2.72 0.00 0.00
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
PHAXIAM Therapeutics (PXMTF) has a Short-Term Debt of $0.00 Mil as of Sep. 2023.
Is PHAXIAM Therapeutics' Short-Term Debt too high?
PHAXIAM Therapeutics' current Short-Term Debt is $0.00 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Short-Term Debt compare to VRTX and REGN?
PHAXIAM Therapeutics' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. PHAXIAM Therapeutics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current Short-Term Debt is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price